Advanced search
Publication Cover
Cancer Investigation Volume 30, 2012 - Issue 2
Submit an article Journal homepage
238
Views
21
CrossRef citations to date
0
Altmetric
CELLULAR AND MOLECULAR BIOLOGY

Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity

Yanfei ZhouDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USACorrespondence[email protected]
,
Rajagopalan SridharDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Liang ShanDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Wei ShaDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Xinbin GuDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
&
Saraswati SukumarDepartments of Oral Pathology, Radiation Oncology, Radiology, Howard University, Washington, DC, USA, Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Pages 119-125 | Published online: 02 Feb 2012
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Loperamide is an FDA-approved antidiarrhea drug which acts on the μ-opioid receptors in the mesenteric plexus of large intestine and exhibits limited side effects. We hypothesized that loperamide might reverse the multidrug resistance (MDR) of human cancer cells to chemotherapeutic agents. MCF-7/MDR1 cells express high level of MDR1 and are resistant to doxorubicin. We found that loperamide significantly enhanced the cytotoxicity of doxorubicin to MCF-7/MDR1 cells in a dose-dependent manner. In conclusion, loperamide reversed the resistance of MCF-7/MDR1 cells to doxorubicin, suggesting that chemotherapy in combination with loperamide may benefit patients with MDR tumors once applied in clinic.

ACKNOWLEDGMENTS

This work was supported in part by grants Howard/Hopkins Partnership grant, U54 CA091431 (YZ and SS) and P20 CA118770 (Y.Z) from the National Institutes of Health, and DAMD17-03-1-0759 from U.S. Army Medical Research and Materiel Command.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,193.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.